Sightdx
3 known investors
Sight develops immune signatures by analyzing live immune cells using AI to generate clinical insights. The company applies proprietary data and machine learning to immune cell analysis for diagnostic and clinical applications.
Founders & leadership
BL
Ben LeshemChief Technology Officer
NM
Nitsan Maayan-RabinowichChief Executive Officer
AC
Asi Cohen-DotanChief Product & Clinical Officer